Vera Therapeutics shares saw a notable increase ahead of an anticipated decision from the U.S. FDA. Meanwhile, Steel Partners made a proposal to acquire InMode for $16.75 per share. Additionally, Greenwich LifeSciences shares rose following approval from the European Medicines Agency regarding its experimental drug GP2.
Greenwich LifeSciences shares climbed after receiving EMA approval for its GP2 drug program, marking a significant regulatory de-risking event in Europe.
Read the full storySteel Partners has launched a formal takeover bid for medical technology firm InMode, sparking market speculation and positive price action.
The biotech firm's stock saw notable buying activity as investors await a critical regulatory ruling on its therapeutic products.